Vancouver, British Columbia--(Newsfile Corp. - August 18, 2022) - EGF Theramed Health Corp. (CSE: TMED) (OTC Pink: EVAHF) (FSE: AUHP) (the "Company" of "EGF") is pleased to announce Connor Yuen as its new Chief Executive Officer. Mr. Connor Yuen is the founder and Chief Investment Officer of Conquest Capital, a Vancouver based private equity fund. He has successfully managed this fund in both public and private markets. Mr Yuen has excelled in his previous experience as a CEO and sits on the board of directors of numerous companies that have achieved market capitalizations of over $100M CAD.
"Coming onto EGF Theramed, I will be looking at world class cannabis opportunities. We will be looking at a vertically integrated businesses from licenced production growth to retail direct to customer sale. I will be bringing on a group of world class managers and advisors who have founded cannabis companies that have had multibillion dollar capitalizations and an experienced finance team that will allow us to take advantage of a cannabis market that is about to turn. Using economics of scale and top tier technology we are looking to take EGF to be a global competitor in the coming months," states Connor Yuen.
The Company thanks and wishes Mr. Jatinder Dhaliwal well in the future endeavours as he resigns from both his CEO and director role.
ABOUT EGF THERAMED HEALTH CORP.
(CSE: TMED) (OTC Pink: EVAHF) (FSE: AUHP)
EGF is a consumer technology company engaged in the provision of biomedical online services for monitoring and treating common health problems. The Company, through its subsidiaries, has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations, as well as medical monitoring device technology. The Company is working to collaborate with other companies for medical technology, equipment protocols and laboratory SOPs.
For more information please contact:
EGF THERAMED HEALTH CORP.
Doug McFaul
Email: dmcfaul@emprisecapital.com
Telephone: (778) 331 8505
Website http://www.theramedhealthcorp.com
CSE Micro-site: http://thecse.com/en/listings/technology/Theramed-Health-Corporation
US OTC Markets (OTCQB): http://www.otcmarkets.com/stock/EVAHF/news
Frankfurt Borse: https://www.boerse-frankfurt.de/equity/egf-theramed-health-corp-1
CAUTIONARY LANGUAGE
All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including with respect to the completion of the Transaction contemplated by the Term Sheet. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/134267
